HU211835A9 - Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure - Google Patents

Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure Download PDF

Info

Publication number
HU211835A9
HU211835A9 HU95P/P00519P HU9500519P HU211835A9 HU 211835 A9 HU211835 A9 HU 211835A9 HU 9500519 P HU9500519 P HU 9500519P HU 211835 A9 HU211835 A9 HU 211835A9
Authority
HU
Hungary
Prior art keywords
prostaglandin
composition
beta
blocking agent
mixture
Prior art date
Application number
HU95P/P00519P
Other languages
English (en)
Hungarian (hu)
Inventor
Laszlo Z Bito
Johan Wilheim Stjernschantz
Original Assignee
Univ Columbia
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21876714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU211835(A9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Columbia, Pharmacia Ab filed Critical Univ Columbia
Publication of HU211835A9 publication Critical patent/HU211835A9/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU95P/P00519P 1987-04-03 1995-06-28 Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure HU211835A9 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3448487A 1987-04-03 1987-04-03

Publications (1)

Publication Number Publication Date
HU211835A9 true HU211835A9 (en) 1995-12-28

Family

ID=21876714

Family Applications (1)

Application Number Title Priority Date Filing Date
HU95P/P00519P HU211835A9 (en) 1987-04-03 1995-06-28 Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure

Country Status (9)

Country Link
EP (1) EP0286903B2 (enExample)
JP (1) JP2726672B2 (enExample)
AT (1) ATE76750T1 (enExample)
AU (1) AU607981B2 (enExample)
CA (1) CA1314220C (enExample)
DE (1) DE3871596T3 (enExample)
ES (1) ES2042625T5 (enExample)
GR (2) GR3004794T3 (enExample)
HU (1) HU211835A9 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1334168C (en) * 1988-04-26 1995-01-31 Louis M. De Santis Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers
US5173507A (en) * 1988-07-18 1992-12-22 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5198545A (en) * 1989-11-13 1993-03-30 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds and process of preparation thereof
US5055467A (en) * 1989-11-13 1991-10-08 Allergan, Inc. Pharmaceutical epinephrine-pilocarpine compounds
US5011856A (en) * 1990-03-12 1991-04-30 Allergan, Inc. Use of prostaglandin F3 α as an ocular hypotensive agent
EP0458587B1 (en) * 1990-05-22 1993-07-14 R-Tech Ueno Ltd. Synergistic combination for ophthalmic use
DE69106777T2 (de) * 1990-05-22 1995-05-18 Ueno Seiyaku Oyo Kenkyujo Kk Behandlung von intraokularem Druck mit einer ophthalmischen synergistischen Kombination.
EP0458590B1 (en) * 1990-05-22 1996-01-10 R-Tech Ueno Ltd. Treatment of ocular hypertention with a synergistic combination
US5238961A (en) * 1990-06-14 1993-08-24 Allergan, Inc. Pgf 1-alcohols and their use as ocular hypotensives
TW210287B (enExample) * 1991-03-01 1993-08-01 Kabushikaisha Ueno Seiyaku Oyo Kenkyujo
ATE207360T1 (de) * 1992-03-19 2001-11-15 R Tech Ueno Ltd Behandlung von augenhochdruck mit betablockern und prostansäurederivaten
JPH06107547A (ja) * 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
ES2105333T3 (es) * 1992-10-13 1997-10-16 Alcon Lab Inc Combinaciones de prostaglandinas y derivados de clonidina para el tratamiento del glaucoma.
US5574066A (en) * 1992-10-28 1996-11-12 Allergan Intraocular pressure reducing 15-acyl prostaglandins
SE9402816D0 (sv) * 1994-08-24 1994-08-24 Pharmacia Ab Method and meams for drug administration
US5698733A (en) * 1994-09-30 1997-12-16 Alcon Laboratories, Inc. Use of 9-deoxy prostaglandin derivatives to treat glaucoma
JP2002501017A (ja) * 1998-01-23 2002-01-15 メルク・シャープ・エンド・ドーム・ベー・ベー 視神経および網膜内の酸素圧を増加させるための方法
KR100875908B1 (ko) * 2001-04-19 2008-12-26 테이카 세이야쿠 가부시키가이샤 약제 및 약제 키트
AU2007200821A1 (en) * 2001-05-31 2007-03-15 Allergan, Inc. Hypotensive lipid and timolol compositions and methods of using same
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
TW200305424A (en) 2002-01-29 2003-11-01 Santen Pharmaceutical Co Ltd Glaucoma-treating agent comprising bunazosin and prostaglandin
AU2003257588A1 (en) * 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
CN1323719C (zh) * 2002-11-18 2007-07-04 参天制药株式会社 由 Rho 激酶抑制剂和β阻断剂构成的青光眼治疗剂
US7186744B2 (en) * 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
DK1905452T3 (da) 2005-07-12 2013-07-01 Kowa Co Middel til forebyggelse eller behandling af glaukom
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US20120184552A1 (en) * 2009-09-17 2012-07-19 Senju Pharmaceutical Co., Ltd. Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin
ES2911174T3 (es) 2010-07-29 2022-05-18 Allergan Inc Soluciones de bimatoprost y timolol sin conservantes
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
TW202344254A (zh) 2011-02-04 2023-11-16 日商興和股份有限公司 青光眼或高眼壓症之預防或治療用之醫藥
JP6193655B2 (ja) * 2012-07-13 2017-09-06 参天製薬株式会社 スルホンアミド化合物の組み合わせ
WO2018033854A1 (en) 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
JPWO2019124487A1 (ja) 2017-12-21 2020-12-10 参天製薬株式会社 オミデネパグの組合せ
JPWO2019124488A1 (ja) 2017-12-21 2020-12-17 参天製薬株式会社 セペタプロストとＲｈｏキナーゼ阻害剤との組み合わせ医薬

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4454154A (en) * 1981-06-23 1984-06-12 American Hospital Supply Corporation Method for treating glaucoma by the topical administration of selectively metabolized beta-blocking agents
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3300933A1 (de) * 1983-01-13 1984-07-19 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von d,l- und d-carazolol als antiglaukommittel sowie arzneimittel, die diese stoffe enthalten
EP0242580B1 (en) * 1986-03-13 1993-04-28 The Trustees Of Columbia University In The City Of New York Use of a, b and c prostaglandins and derivatives thereof to treat ocular hypertension and glaucoma

Also Published As

Publication number Publication date
GR3033721T3 (en) 2000-10-31
EP0286903A1 (en) 1988-10-19
ATE76750T1 (de) 1992-06-15
JPS63313728A (ja) 1988-12-21
ES2042625T3 (es) 1993-12-16
ES2042625T5 (es) 2000-07-16
JP2726672B2 (ja) 1998-03-11
DE3871596T3 (de) 2000-09-07
EP0286903B1 (en) 1992-06-03
DE3871596T2 (de) 1993-01-21
DE3871596D1 (de) 1992-07-09
EP0286903B2 (en) 2000-03-29
AU607981B2 (en) 1991-03-21
CA1314220C (en) 1993-03-09
AU1387088A (en) 1988-10-06
GR3004794T3 (enExample) 1993-04-28

Similar Documents

Publication Publication Date Title
HU211835A9 (en) Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US4952581A (en) Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocular pressure
US4599353A (en) Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
EP0569046B1 (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US10792288B2 (en) Preservative free brimonidine and timolol solutions
USRE39609E1 (en) 8-iso-prostaglandins for glaucoma therapy
JPH0643313B2 (ja) 緑内障の局所治療用組成物
EP3431074A1 (en) Preservative free bimatoprost and timolol solutions
HUP0400548A2 (hu) Belső szemnyomást csökkentő hatóanyag-kombinációk alkalmazása glaukoma kezelésére szolgáló gyógyszerkészítmények előállítására
Hejkal et al. Prostaglandin analogs in the treatment of glaucoma
EP0979652B1 (en) Remedial composition for intraocular hypertension or glaucoma
US20070105950A1 (en) Treatment of ophthalmic disorders using urea and urea derivatives
US4647590A (en) Pharmaceutical compositions and their use in the treatment of glaucoma
Sorbera et al. Bimatoprost
KR0124465B1 (ko) 항녹내장성 안과용 조성물
Podos et al. Experimental compounds to lower intraocular pressure
JPWO2000038689A1 (ja) 高眼圧症あるいは緑内障の処置用医薬組成物
Shaarawy et al. Eye Medications and Its Effect on Orbital Fat and Cosmesis
HK40003602A (en) Preservative free bimatoprost and timolol solutions
KR20080068881A (ko) 안압 강하제인 숙신이미드 유도체
RENGARAJ VENKATESH COMMONLY PRESCRIBED GLAUCOMA EYE DROPS AND ORAL MEDICATIONS
Porcella et al. SHORT COMMUNICATION The synthetic cannabinoid WIN55212-2 decreases the intraocular pressure in human glaucoma resistant to conventional therapies
HK1024170B (en) Remedial composition for intraocular hypertension or glaucoma
JPWO1999018969A1 (ja) 高眼圧症あるいは縁内障の治療用組成物
HK1183793A (en) Preservative free bimatoprost and timolol solutions